NCT04632498 Investigating Biological Markers, Targets, and Intervention for Mood Disorders Status TERMINATED Phase NA
NCT04630964 The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density Status COMPLETED Phase PHASE2
NCT04629599 IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL) Status COMPLETED Phase NA
NCT04623814 the Safety, Tolerability, and Pharmacokinetics Study of HEC113995 Status COMPLETED Phase PHASE1
NCT04623034 Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine Status COMPLETED Phase PHASE1
NCT04621708 Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS Status UNKNOWN Phase NA
NCT04620759 Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04619121 Near-infrared Radiation-transcranial Photobiomodulation for Major Depressive Disorder Status COMPLETED Phase NA
NCT04618263 Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers Status TERMINATED Phase PHASE1
NCT04615234 Clinical Validation of a Combinatorial Pharmacogenomic Approach in Major Depressive Disorder Status UNKNOWN Phase N/A
NCT04607226 Effects of Respiratory-Gated Transcutaneous Vagal Nerve Stimulation in Major Depression (Phase 1) Status COMPLETED Phase NA
NCT04602715 The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression Status UNKNOWN Phase PHASE2
NCT04598607 Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects Status COMPLETED Phase PHASE1
NCT04594616 Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD) Status WITHDRAWN Phase NA
NCT04593563 The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder Status UNKNOWN Phase PHASE2